Next Article in Journal
Acral Lentiginous Melanoma in Situ: A Diagnostic and Management Challenge
Next Article in Special Issue
MicroRNAs in Head and Neck Squamous Cell Carcinoma (HNSCC) and Oral Squamous Cell Carcinoma (OSCC)
Previous Article in Journal
The NK-1 Receptor Antagonist L-732,138 Induces Apoptosis and Counteracts Substance P-Related Mitogenesis in Human Melanoma Cell Lines
Previous Article in Special Issue
Galectins as Cancer Biomarkers
Article Menu

Export Article

Open AccessReview

Midkine: A Novel Prognostic Biomarker for Cancer

Department of Diagnostic Medicine, Graduate School of Medical Sciences, Kumamoto University, 1-1-1 Honjo, Kumamoto, 860-8556, Japan
Author to whom correspondence should be addressed.
Cancers 2010, 2(2), 624-641;
Received: 5 March 2010 / Revised: 3 March 2010 / Accepted: 19 April 2010 / Published: 20 April 2010
(This article belongs to the Special Issue Biomarkers: Oncology Studies)
PDF [410 KB, uploaded 20 April 2010]


Since diagnosis at an early stage still remains a key issue for modern oncology and is crucial for successful cancer therapy, development of sensitive, specific, and non-invasive tumor markers, especially, in serum, is urgently needed. Midkine (MK), a plasma secreted protein, was initially identified in embryonal carcinoma cells at early stages of retinoic acid-induced differentiation. Multiple studies have reported that MK plays important roles in tumor progression, and is highly expressed in various malignant tumors. Because increased serum MK concentrations also have been reported in patients with various tumors, serum MK may have the potential to become a very useful tumor marker. Here, we review and discuss the possibility and usefulness of MK as a novel tumor marker. View Full-Text
Keywords: Midkine; tumor marker; cancer screening; prognostic prediction Midkine; tumor marker; cancer screening; prognostic prediction

Graphical abstract

This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Share & Cite This Article

MDPI and ACS Style

Jono, H.; Ando, Y. Midkine: A Novel Prognostic Biomarker for Cancer. Cancers 2010, 2, 624-641.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top